The journey to the sleeping sickness trial site in Isangi from the DNDi office in Kinshasa begins in the domestic airport of DRC’s capital city and ends more than a day later halfway across the country in a barge crossing the Congo river. In between: hours spent navigating potholed dirt roads, collapsed bridges, checkpoints, and multiple river crossings. Once at Isangi, canoes must be used to reach many of the patients as there are no roads.
Yet for DNDi’s clinical team in DRC, Isangi is one of the easier-to-reach sites. The DRC and the Central African Republic (CAR) both pose daunting challenges that must be overcome to develop better treatments for patients suffering from sleeping sickness.
A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).
As part of the ‘Evénement économique 2017’ that took place on November 9, the Geneva Chamber of Commerce, Industry and Services (CCIG), the Department of Security and Economy (DSE) and the Office for the Promotion of Industries and Technologies (OPI) awarded the Innovation Prize 2017 to the Drugs for Neglected Diseases initiative (DNDi).
DNDi is very pleased to announce the renewed commitment of the Global Health Innovative Technology Fund (GHIT), its donor since 2013, to DNDi projects on leishmaniasis and mycetoma disease
Combining patient data from visceral leishmaniasis clinical trials would give scientists and clinicians more tools to understand and treat the disease which can be fatal if untreated.
GARDP has set up its team, scientific advisory committee, and R&D strategy. Three programmes are underway: neonatal sepsis, gonorrhoea, and an initiative to recover and connect the vital knowledge of scientists in antibiotic drug development. In recent weeks, both the G20 Health Ministers and outgoing WHO Director-General Margaret Chan have expressed support for GARDP and called for more R&D into drug-resistant infections.
Bernard Pécoul, Executive Director, DNDi
Ambitious targets serve the obvious purpose of galvanising the NTD community around a shared goal, and the London Declaration succeeded in bringing new actors to the table and casting a much-needed spotlight on the neglect of these diseases. But the job is far from done, and we should not be lulled into a sense of security or complacency by too much celebrating of good news.
Thirty-five year old Tsadik is a visceral leishmaniasis (VL) patient who is also infected with HIV. He is gaunt, weak and tired, with sunken eyes. Each breath he takes is laboured. Tsadik lives in Abdurafi, a region of northwest Ethiopia that is characterized with high VL-HIV co-infection because VL is endemic….
DNDi is very pleased to announce the renewed commitment of the Global Health Innovative Technology Fund (GHIT), its donor since 2013, to DNDi projects on leishmaniasis and Chagas disease.
Sani sits in the doorway of her one-room house with her baby girl Mel in her arms. A pink sunset illuminates the Durban township of KwaMashu that unfolds below her clifftop house. She looks lovingly at Mel, then takes out a syringe and struggles to give the two-year-old,a medicine that is over 40% alcohol.
Graeme Bilbe, Research & Development Director, DNDi
‘We need to ensure that results of R&D are affordable and available to patients’
DNDi’s R&D Director Graeme Bilbe looks back on 2016 and the exciting advances in DNDi’s portfolio, and explains what he sees as the biggest challenges facing the organization.
Fexinidazole entered into the last stage of clinical development before potential submission to regulatory authorities in 2017 as the first new oral treatment for sleeping sickness, while SCYX-7158* moved to Phase II/III.
Two new chemical entities were nominated as pre-clinical candidates for visceral leishmaniasis, and two Phase II studies to test new treatments for PKDL were designed for launch in Bangladesh, India and Sudan in 2017.
A proof-of-concept study was launched in Bolivia (soon to be extended to Argentina) testing, in patients with chronic Chagas disease, new benznidazole regimens and durations and in combination with fosravuconazole.
Emodepside entered into healthy volunteer Phase I studies in 2016; ABBV-4083 (Tylamac)* entered into full pre-clinical development for the treatment of filarial diseases.
The results of the HIV/TB co-infection ‘super-boosting’ study prompted a change in WHO guidelines, confirming the evidence around the need to increase ritonavir dosages to counter drug-drug interactions.
A phase II/III study to test fosravuconazole in eumycetoma patients was designed for launch in Sudan in 2017.
A Phase II/III study was launched in Malaysia – soon to be extended to other countries – combining ravidasvir and sofosbuvir.
Our staff, partners, and stakeholders share their highlights from 2016.
The Norwegian Agency for Development Cooperation (Norad) has extended its financial support to DNDi with additional funding.